These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32815556)

  • 1. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
    Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
    Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
    Wang W; Dong ML; Zhang W; Liu T
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-based knockdown of multidrug resistance-associated protein 1 is sufficient to reverse multidrug resistance of human lung cells.
    Shao SL; Cui TT; Zhao W; Zhang WW; Xie ZL; Wang CH; Jia HS; Liu Q
    Asian Pac J Cancer Prev; 2014; 15(24):10597-601. PubMed ID: 25605145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
    Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
    Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
    Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
    Tian R; Zhang C; Xiong F; Chen H
    Front Biosci (Landmark Ed); 2020 Mar; 25(5):948-960. PubMed ID: 32114419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
    Fang Z; Chen W; Yuan Z; Liu X; Jiang H
    Biomed Pharmacother; 2018 May; 101():536-542. PubMed ID: 29505924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
    Zuo Y; Yang D; Yu Y; Xiang M; Li H; Yang J; Li J; Jiang D; Zhou H; Xu Z; Yu Z
    Mol Med Rep; 2018 Mar; 17(3):3497-3502. PubMed ID: 29257330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.